Antiemetic agents

Published on 07/02/2015 by admin

Filed under Anesthesiology

Last modified 07/02/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 2445 times

Antiemetic agents

Robert J. Trainer, DO, MBA

Nausea and vomiting represent an extremely distressing and financially costly problem, the risk of which has increased as the fields of anesthesia, surgery, and cancer chemotherapy have advanced. Many drugs are now available to treat and provide prophylaxis against the myriad of situations that give rise to nausea and vomiting (Figures 98-1 and 98-2).

image
Figure 98-1 Chemical activation of the vomiting center is mediated via the chemoreceptor trigger zone (CTZ), which is sensitive to the presence of toxins and poisons in the bloodstream.
image
Figure 98-2 Medications used to treat nausea and vomiting and their sites of action. RAs, Receptor antagonists.

From studies in the 1950s, a model of the emetic reflex emerged (which has been subsequently validated), consisting of a chemoreceptor trigger zone (CTZ) in the area postrema and a vomiting center in the brainstem. Nausea and vomiting result from chemical or neural stimulation of the vomiting center. Chemical activation is mediated via the CTZ, which is sensitive to the presence of toxins and poisons in the bloodstream (see Figure 98-1). Neural activation occurs as a result of information coming directly from the frontal lobes of the brain, the digestive tract, and the balancing mechanism of the inner ear.

The CTZ is susceptible to stimulation from the release of dopamine and serotonin (5-HT) in the blood and cerebrospinal fluid and may also be activated by opioids and certain anesthetic agents. In addition, the release of 5-HT from the gastrointestinal tract can stimulate the CTZ. The vestibular system sends input to the vomiting center in response to changes in motion and pressure. The reflex afferent pathway from the cerebral cortex stimulates the vomiting center in response to such factors as pain, anxiety, and visual, sensory, or cognitive overload (see Figure 98-2).

Clinical scenarios in which nausea and vomiting are common include cancer chemotherapy, the postoperative period, headache syndromes, and the use of opioids. Optimization of each potentially overlapping scenario requires a tailored approach, although certain principles are worth noting. For example, factors that increase a patient’s risk for developing postoperative nausea and vomiting (PONV) include increasing age, premenopausal women, obesity, previous history of motion sickness or PONV, anxiety, gastroparesis, and type and duration of the surgical procedure (e.g., laparoscopy, strabismus, middle ear procedures). Anesthesiologists have little, if any, control over these surgical factors. However, they do have control over many other factors that influence PONV (e.g., preanesthetic medication, anesthetic drugs and techniques, and postoperative pain management). PONV has an overall incidence of approximately 34% in patients receiving a general anesthetic without preoperative antiemetic therapy, with reductions of PONV by 26% with prophylactic administration of ondansetron, dexamethasone, or droperidol. Furthermore, prevention of PONV is much more effective than treatment administered after symptoms occur. Total intravenous anesthesia is preferred over inhalation agents, and the use of nonopioid analgesics—such as ketorolac, paracetamol, nonsteroidal anti inflammatory drugs, or cyclooxygenase-2 inhibitors—are often given along with morphine as part of multimodal analgesia after major operations. The use of regional anesthesia can benefit patients who are expected to have high postoperative opiate requirements.

In an attempt to reduce the risk of PONV if patients are expected to be placed on opioid therapy, current recommendations include a bowel regimen consisting of a motility agent (senna) and a stool softener (docusate) to avoid opiate-induced constipation and consequent nausea. In patients who are able to drink, psyllium and osmotic laxatives have also been suggested as beneficial.

Today, the standard of care for prevention of chemotherapy-induced nausea and vomiting (CINV) for highly and moderately emetogenic chemotherapy is a 5-HT3-receptor antagonist, dexamethasone, with or without aprepitant or fosaprepitant.

Finally, the relatively low risk of side effects from the use of antiemetic drugs overall was confirmed in a large meta-analysis that included 737 studies involving 103,237 people and the use of eight commonly used drugs: droperidol, metoclopramide, ondansetron, tropisetron, dolasetron, dexamethasone, cyclizine, and granisetron. The authors observed that between 1 and 5 out of every 100 people experienced a mild side effect, such as sedation or headache, when given an antiemetic drug.

Antidopaminergic drugs

Antidopaminergic drugs (D2-receptor antagonists) include butyrophenones (haloperidol, droperidol), phenothiazines, domperidone, and metoclopramide. The D2-receptor antagonists combined with the 5-HT3 antagonists make up the largest number of medications currently used for treating nausea. The D2-receptor antagonists are also the oldest class of medications used in this scenario. The D2 receptor in the CTZ is the primary target for all drugs currently used for preventing or treating PONV and CINV; domperidone (used primarily for nausea due to gastroenteritis) is the exception owing to its inability to cross the blood-brain barrier. Olanzapine, an antipsychotic, has antagonistic properties at the D2, acetylcholine, and 5-HT3 receptors. The well-known antiemetic effect of propofol may be due to a D2 antagonism, 5-HT3 antagonism, or a cannabinoid agonism.

Side effects

Antidopaminergic drugs should not be used in patients with Parkinson disease, restless leg syndrome, or any other disorder in which dopaminergic drugs are used to treat the signs and symptoms of the disease. Extrapyramidal reactions, sedation, diarrhea, and orthostatic hypotension can occur with all antidopaminergic drugs used in the treatment of PONV. Haloperidol is the drug in this class that is most likely to be implicated as the cause of excessive sedation, and prochlorperazine is responsible for most cases of orthostatic hypotension.

The U.S. Food and Drug Administration requires a boxed warning on droperidol related to the drug’s propensity to prolong the QT interval; therefore, patients who receive droperidol intraoperatively should have electrocardiographic monitoring for 4 h postoperatively.

Buy Membership for Anesthesiology Category to continue reading. Learn more here

Related posts:

Default ThumbnailAnesthesia information management systems Dexmedetomidine Croup versus epiglottitis Default ThumbnailMultimodal analgesia Default ThumbnailBlood gas temperature correction Physiologic determinants of cardiac output